Alopecia With Endocrine Therapies in Patients With Cancer

    September 2013 in “ Oncologist ”
    Vishal Raj Saggar, Shenhong Wu, Maura N. Dickler, Mario E. Lacouture
    Studysummary This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on theoncologist.alphamedpress.org →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Hair Shaft Abnormalities After Chemotherapy and Tamoxifen Therapy in Patients With Breast Cancer Evaluated by Optical Coherence Tomography British Journal of Dermatology · 2012
    2. Evidence-Based Treatments for Female Pattern Hair Loss: A Summary of a Cochrane Systematic Review British Journal of Dermatology · 2012
    3. Hair Loss in Women: Medical and Cosmetic Approaches to Increase Scalp Hair Fullness British Journal of Dermatology · 2011
    4. Hair Loss in Women The New England Journal of Medicine · 2007
    5. Protection Against Chemotherapy-Induced Alopecia Pharmaceutical Research · 2006
    6. Treatment of Hair Loss The New England Journal of Medicine · 1999
    7. The Biology of Hair Follicles The New England Journal of Medicine · 1999